Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.58 |
| ▸ | PLAU | P00749 | 3/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29173421 | 0.86 | GRM5 (0.47) | GRM5CDK5CDK5R1NPC1RAB9A | |
| SCHEMBL30206317 | 0.86 | GRM5 (0.47) | GRM5CDK5CDK5R1NPC1RAB9A | |
| SCHEMBL29988155 | 0.77 | GRM5 (0.48) | GRM5PLAUSMN1; SMN2 | |
| SCHEMBL22552121 | 0.77 | GRM5 (0.48) | GRM5PLAUSMN1; SMN2 | |
| SCHEMBL4899989 | 0.75 | KDM4E (0.44) | GRM5CDK5CDK5R1NPC1RAB9A | |
| SCHEMBL3860010 | 0.74 | GRM5 (0.72) | GRM5PLAUNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8071643 | 0.73 | PLAU (0.46) | GRM5PLAUHTTASIC3SMN1; SMN2 | |
| SCHEMBL30205978 | 0.73 | PLAU (0.46) | GRM5PLAUHTTASIC3SMN1; SMN2 | |
| SCHEMBL12389585 | 0.73 | PLAU (0.46) | GRM5PLAUHTTASIC3SMN1; SMN2 | |
| SCHEMBL3868810 | 0.73 | GRM5 (0.73) | GRM5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |